<DOC>
	<DOC>NCT01921855</DOC>
	<brief_summary>This is the first in humans study of BAY86-6150 (B0189) in non-bleeding subjects with moderate or severe congenital hemophilia A or B with or without inhibitors. This is a randomized, double-blind, placebo-controlled, single-dose, dose escalation study. It is designed to investigate the safety, tolerability, potential immunogenicity, pharmacokinetic and pharmacodynamic profile of BAY86-6150 (B0189) and to determine a dose or range of doses to be examined in subsequent studies.</brief_summary>
	<brief_title>Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>History of moderate or severe congenital hemophilia A or B with or without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) Male subjects 1865 years of age inclusive Able to dismiss factor replacement therapy during the course of the study unless required for the treatment of an acute bleeding episode Written informed consent Willing and able to comply with the requirements of the protocol Have adequate venous access Willing to use an effective method of contraception until Day 30 of their study participation Received factor replacement therapy or treatment with any other procoagulant therapeutics, or any antifibrinolytic agents, including blood products, at anytime within 5 days prior to administration of investigational medicinal product (IMP) Planned administration of factor replacement therapy or treatment with any other procoagulant therapeutics or any antifibrinolytic agents, including blood products, at anytime during the study period Acute bleeding episode or any ongoing bleeding episode at any time within 7 days prior to administration IMP Clinically relevant coagulation disorder other than congenital hemophilia A or B History of angina or receiving treatment for angina History of coronary atherosclerotic disease, disseminated intravascular coagulopathy, or stage 2 hypertension defined as systolic blood pressure (SBP) &gt;/= 160 mmHg or diastolic blood pressure (DBP) &gt;/= 90 mmHg History of transient ischemic attack, stroke, myocardial infarction, coronary artery disease, congestive heart failure, or thromboembolic event Active infection on day of IMP administration or septicemia at any time within 30 days prior to administration of IMP</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>